Fabrazyme®
Fabrazyme (agalsidase beta-rch) for Fabry disease is our second enzyme replacement therapy for a lysosomal storage disorder. Fabry disease causes organ complications, heart disease, stroke, and renal disease.
Please see the attached Product Information and Consumer Medicine Information for further details about this product.
Genzyme Australasia recommends patient always seek the medical advice of their healthcare professional.
|
|
|
| |
Contact Us: |
|
Level 1, Building C,
12-24 Talavera Road
North Ryde NSW 2113
P: 612 9978 3900
F: 612 9889 3900
Mailing Address:
PO Box 282
North Ryde B/C NSW 1670
General Email
Medical Enquiries Email |
|
|
|
Genzyme Australasia Home
